You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesoximetasone
Accession NumberDB00547  (APRD00910)
TypeSmall Molecule
GroupsApproved
DescriptionA topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc. [PubChem]
Structure
Thumb
Synonyms
(11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-methyl-delta(1)-corticosterone
Desoximetason
Desoximetasona
Désoximétasone
Desoximetasonum
Desoxymethasone
External Identifiers
  • Hoe 304
  • R 2113
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desoxi Cream 0.05%Cream0.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-12-22Not applicableCanada
Desoxi Cream 0.25%Cream0.25 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-12-22Not applicableCanada
Desoxi Gel 0.05%Gel0.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.2000-04-13Not applicableCanada
DesoximetasoneOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1985-01-17Not applicableUs
TopicortOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1985-01-17Not applicableUs
TopicortCream0.25 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
TopicortSpray2.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2013-04-11Not applicableUs
Topicort 0.25%Cream.25 %TopicalHoechst Canada Inc.1977-12-311996-08-29Canada
Topicort Crm 2.5mg/gmCream2.5 mgTopicalHoechst Roussel Canada Inc.1994-12-311998-08-12Canada
Topicort GelGel0.05 %TopicalValeant Canada Lp Valeant Canada S.E.C.1996-12-04Not applicableCanada
Topicort Gel 0.05%Gel.05 %TopicalHoechst Canada Inc.1988-12-311997-08-05Canada
Topicort Gel 0.05%Gel.5 mgTopicalHoechst Roussel Canada Inc.1995-12-311998-08-12Canada
Topicort MildCream0.05 %TopicalValeant Canada Lp Valeant Canada S.E.C.1996-11-07Not applicableCanada
Topicort Mild .05%Cream.05 %TopicalHoechst Canada Inc.1980-12-311997-08-05Canada
Topicort Mild Cream 0.5mg/gmCream.5 mgTopicalHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Topicort OintmentOintment0.25 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
Topicort Ointment 2.5mg/gmOintment2.5 mgTopicalHoechst Roussel Canada Inc.1993-12-311999-08-11Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesoximetasoneOintment2.5 mg/gTopicalTeligent Pharma, Inc.2016-02-25Not applicableUs
DesoximetasoneCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1990-11-30Not applicableUs
DesoximetasoneGel.5 mg/gTopicalVersa Pharm Incorporated2011-04-11Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2012-09-28Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalActavis Pharma, Inc.2016-11-17Not applicableUs
DesoximetasoneGel.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1998-07-14Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalActavis Pharma, Inc.2016-03-31Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalNovel Laboratories, Inc.2016-05-10Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalVersa Pharm Incorporated2015-06-30Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2010-06-29Not applicableUs
DesoximetasoneGel.5 mg/gTopicalPhysicians Total Care, Inc.2008-02-29Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1996-06-07Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalPerrigo New York Inc2006-10-24Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalA S Medication Solutions2006-10-24Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalGlenmark Pharmaceuticals Inc., Usa2013-09-20Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalRebel Distributors Corp1990-11-30Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalPhysicians Total Care, Inc.1994-06-23Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalVersa Pharm Incorporated2014-09-12Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1990-11-30Not applicableUs
DesoximetasoneGel.5 mg/gTopicalGroupe Parima Inc2016-08-12Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalProficient Rx LP2006-10-24Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalPerrigo New York Inc2015-05-14Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalPhysicians Total Care, Inc.2008-05-08Not applicableUs
TopicortCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1990-11-30Not applicableUs
TopicortGel.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1998-07-14Not applicableUs
TopicortOintment2.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1992-12-15Not applicableUs
TopicortCream2.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1990-11-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Espersonsanofi-aventis
Flubasonsanofi-aventis
Topicort LPsanofi-aventis
Topisolonsanofi-aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4E07GXB7AU
CAS number382-67-2
WeightAverage: 376.4617
Monoisotopic: 376.204987621
Chemical FormulaC22H29FO4
InChI KeyVWVSBHGCDBMOOT-IIEHVVJPSA-N
InChI
InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[[email protected]](C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Structured Indications
PharmacodynamicsLike other topical corticosteroids, desoximetasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Desoximetasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mechanism of actionThe precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. This is achieved first by the drug binding to the glucocorticoid receptors which then translocates into the nucleus and binds to DNA causing various activations and repressions of genes. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionTopical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingBound to plasma proteins in varying degrees.
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of eliminationCorticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.Pharmacokinetic studies in men with Desoximetasone Cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%)
Half lifeThe half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
ClearanceNot Available
ToxicityTopically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoximetasone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Desoximetasone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoximetasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoximetasone.Approved
AldesleukinDesoximetasone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Desoximetasone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Desoximetasone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoximetasone.Approved
AmiodaroneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BDesoximetasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoximetasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoximetasone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desoximetasone.Approved, Investigational
AprepitantThe serum concentration of Desoximetasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Desoximetasone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Desoximetasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoximetasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoximetasone.Approved, Investigational
BazedoxifeneThe serum concentration of Desoximetasone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideDesoximetasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoximetasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Desoximetasone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desoximetasone.Investigational
Bismuth SubcitrateThe bioavailability of Desoximetasone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Desoximetasone can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoximetasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoximetasone.Investigational
BumetanideDesoximetasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoximetasone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Desoximetasone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Desoximetasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoximetasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoximetasone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Desoximetasone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoximetasone.Approved, Investigational
CeritinibDesoximetasone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoximetasone.Approved, Vet Approved
ChlorothiazideDesoximetasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Desoximetasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneDesoximetasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Desoximetasone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoximetasone.Approved
CobicistatThe serum concentration of Desoximetasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Desoximetasone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoximetasone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoximetasone.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Desoximetasone.Investigational
DarunavirThe serum concentration of Desoximetasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Desoximetasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoximetasone.Approved, Vet Approved
DienestrolThe serum concentration of Desoximetasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Desoximetasone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoximetasone.Approved
DihydrotestosteroneDesoximetasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoximetasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoximetasone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Desoximetasone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Desoximetasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoximetasone.Approved
EstradiolThe serum concentration of Desoximetasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Desoximetasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Desoximetasone can be increased when it is combined with Estrone.Approved
Etacrynic acidDesoximetasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Desoximetasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoximetasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoximetasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoximetasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desoximetasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Desoximetasone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoximetasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoximetasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desoximetasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desoximetasone.Vet Approved
FluoxymesteroneDesoximetasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoximetasone.Approved, Investigational
FosaprepitantThe serum concentration of Desoximetasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Desoximetasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideDesoximetasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Desoximetasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Desoximetasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Desoximetasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Desoximetasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Desoximetasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoximetasone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desoximetasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoximetasone.Approved, Investigational
HydrochlorothiazideDesoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDesoximetasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoximetasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desoximetasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desoximetasone.Approved
IdelalisibThe serum concentration of Desoximetasone can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Desoximetasone.Approved
IndapamideDesoximetasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Desoximetasone can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoximetasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoximetasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Desoximetasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoximetasone.Withdrawn
ItraconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoximetasone.Experimental
KetoconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoximetasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desoximetasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoximetasone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoximetasone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoximetasone.Approved
LumacaftorThe serum concentration of Desoximetasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoximetasone.Approved, Investigational
MagaldrateThe bioavailability of Desoximetasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Desoximetasone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Desoximetasone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Desoximetasone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoximetasone.Approved
Magnesium TrisilicateThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoximetasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoximetasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoximetasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoximetasone.Approved
MestranolThe serum concentration of Desoximetasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoximetasone.Withdrawn
MethallenestrilThe serum concentration of Desoximetasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDesoximetasone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneDesoximetasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneDesoximetasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Desoximetasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Desoximetasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Desoximetasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoximetasone.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoximetasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoximetasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoximetasone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoximetasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoximetasone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Desoximetasone.Investigational
NefazodoneThe serum concentration of Desoximetasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoximetasone.Approved
NevirapineThe serum concentration of Desoximetasone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoximetasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoximetasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoximetasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoximetasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desoximetasone.Vet Approved
OxandroloneDesoximetasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoximetasone.Approved
OxymetholoneDesoximetasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoximetasone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoximetasone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Desoximetasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Desoximetasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Desoximetasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoximetasone.Approved, Vet Approved
PhenytoinThe serum concentration of Desoximetasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoximetasone.Approved, Investigational
PiretanideDesoximetasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoximetasone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoximetasone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Desoximetasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDesoximetasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Desoximetasone can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Desoximetasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoximetasone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desoximetasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Desoximetasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneDesoximetasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Desoximetasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.Experimental, Investigational
RifabutinThe serum concentration of Desoximetasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Desoximetasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Desoximetasone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Desoximetasone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desoximetasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Desoximetasone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoximetasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoximetasone.Approved
SaquinavirThe serum concentration of Desoximetasone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Desoximetasone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoximetasone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Desoximetasone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Desoximetasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desoximetasone.Investigational
St. John's WortThe serum concentration of Desoximetasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololDesoximetasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoximetasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoximetasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoximetasone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Desoximetasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Desoximetasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Desoximetasone.Approved
TelithromycinThe serum concentration of Desoximetasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoximetasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desoximetasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoximetasone.Approved
TestosteroneDesoximetasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Desoximetasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoximetasone.Approved
TiboloneThe serum concentration of Desoximetasone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoximetasone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoximetasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoximetasone.Approved
TorasemideDesoximetasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoximetasone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideDesoximetasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desoximetasone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoximetasone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDesoximetasone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoximetasone.Approved
ZeranolThe serum concentration of Desoximetasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desoximetasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoximetasone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Kieslich, K., Kerb, U. and Raspe, G.; U S . Patent 3,232,839; February 1,1966; assigned to
Schering AG, Germany.

General ReferencesNot Available
External Links
ATC CodesD07XC02D07AC03
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (93.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9825
Caco-2 permeable+0.9022
P-glycoprotein substrateSubstrate0.7712
P-glycoprotein inhibitor INon-inhibitor0.7281
P-glycoprotein inhibitor IINon-inhibitor0.7049
Renal organic cation transporterNon-inhibitor0.7676
CYP450 2C9 substrateNon-substrate0.8621
CYP450 2D6 substrateNon-substrate0.9066
CYP450 3A4 substrateSubstrate0.7565
CYP450 1A2 substrateNon-inhibitor0.927
CYP450 2C9 inhibitorNon-inhibitor0.9028
CYP450 2D6 inhibitorNon-inhibitor0.8847
CYP450 2C19 inhibitorNon-inhibitor0.9486
CYP450 3A4 inhibitorNon-inhibitor0.6179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8969
Ames testNon AMES toxic0.9138
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.6856 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9473
hERG inhibition (predictor II)Inhibitor0.5842
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Nycomed us inc
  • Perrigo new york inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals north america inc
  • Altana inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical0.25 %
CreamTopical.5 mg/g
CreamTopical2.5 mg/g
GelTopical.5 mg/g
OintmentTopical.5 mg/g
OintmentTopical2.5 mg/g
SprayTopical2.5 mg/mL
CreamTopical.25 %
CreamTopical2.5 mg
GelTopical0.05 %
GelTopical.05 %
GelTopical.5 mg
CreamTopical0.05 %
CreamTopical.05 %
CreamTopical.5 mg
OintmentTopical0.25 %
OintmentTopical2.5 mg
Prices
Unit descriptionCostUnit
Topicort 0.25% Ointment 60 gm Tube312.62USD tube
Topicort 0.25% Cream 60 gm Tube230.24USD tube
Desoximetasone 0.25% Ointment 60 gm Tube229.01USD tube
Desoximetasone 0.25% Cream 60 gm Tube204.91USD tube
Desoximetasone 0.05% Cream 60 gm Tube189.99USD tube
Desoximetasone 0.05% Gel 60 gm Tube174.86USD tube
Topicort 0.25% Ointment 15 gm Tube94.14USD tube
Topicort 0.05% Gel 15 gm Tube74.59USD tube
Desoximetasone 0.25% Ointment 15 gm Tube68.86USD tube
Topicort 0.25% Cream 15 gm Tube64.99USD tube
Desoximetasone 0.25% Cream 15 gm Tube59.94USD tube
Desoximetasone 0.05% Gel 15 gm Tube54.46USD tube
Desoximetasone 0.05% Cream 15 gm Tube51.25USD tube
Topicort 0.25% cream4.32USD g
Topicort lp 0.05% cream3.45USD g
Desoximetasone 0.05% cream1.29USD g
Topicort 0.25 % Cream0.73USD g
Desoximetasone 0.25% cream0.63USD g
Topicort Mild 0.05 % Cream0.5USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5990100 No1998-03-242018-03-24Us
US8277780 No2008-09-012028-09-01Us
US8715624 No2006-05-262026-05-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point217 °CPhysProp
water solubility42.1 mg/LNot Available
logP2.35HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.031 mg/mLALOGPS
logP2.13ALOGPS
logP2.35ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.44ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity101.17 m3·mol-1ChemAxon
Polarizability40.09 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schafer-Korting M: Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2000 Mar-Apr;13(2):93-103. [PubMed:10754457 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:46